EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer

Nelson Rangel, Valentina Camargo, Giovanny Castellanos, Maribel Forero-Castro, Milena Rondón-Lagos

Gene Expression · 28.06.2024 · 23 (2) · 116-126

DOI: 10.14218/ge.2023.00154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gene Expression, online erschienen am 10.04.2024. Verfasst von Nelson Rangel und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the type of cancer with the highest incidence and mortality rates in women in the world. In the treatment of this neoplasia, several therapies are applied, including radiotherapy, hormonal therapy, chemotherapy, and biological therapy. Although most patients respond to these types of therapy, some patients over time, develop resistance or eventually relapse. Considering the above, future therapeutic concepts in BC are being directed at individualization of therapy and escalation of treatment based on tumor biology through the use of gene therapy. In this regard, a new genomic engineering technology, called the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9), has acquired great importance in recent years, as a potential gene editing tool, extensively applied in human cancer research and cancer treatment. The aim of this review was to describe the advantages, limitations, and applications of CRISPR gene editing technology in BC treatment. Our review emphasizes the innovative facets and profound importance of CRISPR gene editing technology within the BC treatment landscape. Additionally, it provides valuable information to consider when evaluating the risks associated with the implementation of CRISPR-Cas9 technology in BC therapy.

Zitieren

APA

Rangel, N., Camargo, V., Castellanos, G., Forero-Castro, M., & Rondón-Lagos, M. (2024). Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer. Gene Expression, 23(2), 116-126. https://doi.org/10.14218/ge.2023.00154

Vancouver

Rangel N, Camargo V, Castellanos G, Forero-Castro M, Rondón-Lagos M. Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer. Gene Expression. 2024;23(2):116-126. doi:10.14218/ge.2023.00154

BibTeX
@article{Rangel2024,
  author = {Rangel, Nelson and Camargo, Valentina and Castellanos, Giovanny and Forero-Castro, Maribel and Rondón-Lagos, Milena},
  title = {Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer},
  journal = {Gene Expression},
  year = {2024},
  volume = {23},
  number = {2},
  pages = {116--126},
  doi = {10.14218/ge.2023.00154}
}
Kostenlos starten →